2023 ´ëÇÑ»ý¹°Ä¡·áÁ¤½ÅÀÇÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À° : 2023-09-02
±³À°ÀÏÀÚ : 2023-09-02
±³À°Àå¼Ò : ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀǽÇ
±³À°ÁÖÁ¦ : 2023 ´ëÇÑ»ý¹°Ä¡·áÁ¤½ÅÀÇÇÐȸ Ãß°èÇмú´ëȸ ¹× ¿¬¼ö±³À°
ÁÖÃÖ±â°ü : ´ëÇÑ»ý¹°Ä¡·áÁ¤½ÅÀÇÇÐȸ
´ã´çÀÚ : ±èÁø¿Á
¿¬¶ôó : 010-2563-6902
À̸ÞÀÏ : ksbtp.svc@gmail.com
±³À°Á¾·ù : Á¤½Å°Ç°ÀÇÇаú
Âü¼®¿¹»óÀÎ : 150¸í
Èñ¸ÁÆòÁ¡ : 6Á¡
Áö¿ª : ±¤ÁÖ±¤¿ª½Ã
±³À°½Ã°£ : 12 ½Ã°£ 20ºÐ
¼¼ºÎ¼ö°·á : 40,000¿ø
ºñ°í Àü¹®ÀÇ 40,000¿ø (ÇöÀåµî·Ï 50,000¿ø)±ºÀü¹®ÀÇ, °øº¸ÀÇ, Àü°øÀÇ 20,000¿ø (ÇöÀåµî·Ï 30,000¿ø)Æò»ýȸ¿ø ¸éÁ¦ (ÇöÀåµî·Ï 10,000¿ø)
±¸ºÐ ¿ùÀÏ °ÀÇ½Ç ½Ã°£ ±³À°Á¦¸ñ °»ç¸í(¼Ò¼Ó) Çʼö°ú¸ñ
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 09:40~10:05 What we learn about bipolar disorder from large-scale neuroimaging ±è°æ¿ø(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 10:05~10:30 Global neuroimaging studies of MDD through worldwide data sharing À±¼®È£(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 10:30~10:55 Cross-disorder comparison of major neuropsychiatric disorder ±èº´ÈÆ(¿¬¼¼ÀÇ´ë)
Åä·Ð 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 10:55~11:05 Q&A ( )
ÈÞ½Ä 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 11:05~11:15 CoffeeBreak ( )
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 11:15~11:40 An update of Cortico-Striato-Thalamo-Cortical (CSTC) loop underlying OCD ±èÁÖ¿Ï(Àü³²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 11:40~12:05 Neuroimaging findings of traditional and third-wave CBT in OCD ÀÌ»ó¿ø(°æºÏÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 12:05~12:30 Integrative understanding of functional brain network underlying OCD À̽ÂÀç(°æºÏÀÇ´ë)
Åä·Ð 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 12:30~12:40 Q&A ( )
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 12:40~13:40 Anti-anxiety effect of olanzapine À̽ÂÀç(°æºÏÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 13:40~14:05 ATN classification of Alzheimer¡¯s disease and diagnostic biomarkers °ø³ª¿µ(°è¸íÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 14:05~14:30 Disease-modifying therapy for Alzheimer¡¯s disease Àü¼Ò¿¬(Ãæ³²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 14:30~14:55 The role of cognitive intervention and digital therapeutics ±èÇý±Ý(¿µ³²ÀÇ´ë)
Åä·Ð 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 14:55~15:05 Q&A ( )
ÈÞ½Ä 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 15:05~15:15 CoffeeBreak ( )
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 15:15~15:40 Substance use trend in Korean adolescent: epidemiology and fact sheet ±èÁØ¿ø(´ë±¸ °¡Å縯ÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 15:40~16:05 Fentanyl use: clinical manifestations, medical and psychopharmacological treatment Á¶¼ÒÇý(¿µ³²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 16:05~16:30 Psychosocial treatment of substance use disorder in adolescent. ÀÌÈ£ÁØ(°è¸íÀÇ´ë)
Åä·Ð 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç A·ë 16:30~16:40 Q&A ( )
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 09:40~10:05 Emotion recognition deficits in psychiatric disorder ¹é¼±È(Àü³²ÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 10:05~10:30 Present and near future of emotion recognition ¾çÇüÁ¤(Àü³²´ë ÀΰøÁö´ÉÇкÎ)
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 10:30~10:55 Intervention of psychiatric disorder using ICT & emotion recognition ±è½Â¿ø(Àü³²´ë ÀΰøÁö´ÉÇкÎ)
Åä·Ð 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 10:55~11:05 Q&A ( )
ÈÞ½Ä 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 11:05~11:15 CoffeeBreak ( )
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 11:15~11:40 Overview of CIAS ±è¼ºÁø(ÀÎÁ¦ÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 11:40~12:05 Pharmacologic interventions of CIAS ±è¼¿µ(¼¿ïÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 12:05~12:30 Nonpharmacologic interventions of CIAS Á¤µµ¿î(ÀÎÁ¦ÀÇ´ë)
Åä·Ð 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 12:30~12:40 Q&A ( )
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 13:40~14:15 ChatGPT: Artificial Intelligence & Mental Health Ȳ½Â¿ø(¼¿ï´ë ÄÄÇ»ÅÍ°øÇкÎ)
Åä·Ð 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 14:15~14:20 Q&A ( )
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 14:20~15:00 ChatGPT and the Future of Medical Writing ¾È»óÁø(ÀÎÁ¦ÀÇ´ë ¾à¸®ÇÐ)
Åä·Ð 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 15:00~15:05 Q&A ( )
ÈÞ½Ä 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 15:05~15:15 CoffeeBreak ( )
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 15:15~15:40 Tardive dyskinesia and valbenazine Á¤Áö¿î(ºÎ»êÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 15:40~16:05 Parkinson ±èÇö¼ö(µ¿¾ÆÀÇ´ë)
±³À°½Ã°£ 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 16:05~16:30 Depression and dextromethorphan/buproprion Àå½ÂÈ£(¿ø±¤ÀÇ´ë)
Åä·Ð 09¿ù 02ÀÏ ±¤ÁÖ ±è´ëÁßÄÁº¥¼Ç¼¾ÅÍ 2Ãþ ȸÀÇ½Ç B·ë 16:30~16:40 Q&A ( )